REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Clinical trials for REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis early-stage study tests the safety and best dose of two drugs—ibrutinib and lenalidomide—given together to people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a dose that is safe and tolerable, while also seeing …
Matched conditions: REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…
Matched conditions: REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs, nivolumab and lenalidomide, in people with non-Hodgkin or Hodgkin lymphoma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combination works at shrinking tumors. Ab…
Matched conditions: REFRACTORY LYMPHOPLASMACYTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC